310 related articles for article (PubMed ID: 33868261)
21. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
[TBL] [Abstract][Full Text] [Related]
22. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
23. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
24. SLC17A2 Expression Correlates with Prognosis and Immune Infiltrates in Hepatocellular Carcinoma.
Wang Z; Chen X; Jiang Z
Comb Chem High Throughput Screen; 2022; 25(12):2001-2015. PubMed ID: 35081886
[TBL] [Abstract][Full Text] [Related]
25. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.
Liu T; Wu H; Qi J; Qin C; Zhu Q
Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653
[TBL] [Abstract][Full Text] [Related]
26. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
[TBL] [Abstract][Full Text] [Related]
27. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
[TBL] [Abstract][Full Text] [Related]
28. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.
Wen DG; Zhao XP; You Y; Liu ZJ
Cancer Immunol Immunother; 2021 Mar; 70(3):773-786. PubMed ID: 32989553
[TBL] [Abstract][Full Text] [Related]
29. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.
Huo J; Wu L; Zang Y; Dong H; Liu X; He F; Zhang X
BMC Cancer; 2021 Jan; 21(1):31. PubMed ID: 33413205
[TBL] [Abstract][Full Text] [Related]
30. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.
Xiao Y; Najeeb RM; Ma D; Yang K; Zhong Q; Liu Q
J Exp Clin Cancer Res; 2019 Nov; 38(1):458. PubMed ID: 31703591
[TBL] [Abstract][Full Text] [Related]
32. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.
Li B; Shao Q; Ji D; Li F; Guo X; Chen G
Diagn Pathol; 2014 Oct; 9():209. PubMed ID: 25338637
[TBL] [Abstract][Full Text] [Related]
33. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.
Zhu S; Huang X; Zhang K; Tan W; Lin Z; He Q; Chen Y; Shang C
Cancer Med; 2019 Dec; 8(18):7679-7692. PubMed ID: 31674731
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.
Wei T; Zhang LN; Lv Y; Ma XY; Zhi L; Liu C; Ma F; Zhang XF
Oncotarget; 2014 Nov; 5(21):10307-17. PubMed ID: 25333264
[TBL] [Abstract][Full Text] [Related]
35. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
36. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.
Kunadirek P; Ariyachet C; Sriphoosanaphan S; Pinjaroen N; Sirichindakul P; Nookaew I; Chuaypen N; Tangkijvanich P
Sci Rep; 2021 May; 11(1):11201. PubMed ID: 34045534
[TBL] [Abstract][Full Text] [Related]
37. CFHR3 is a potential novel biomarker for hepatocellular carcinoma.
Liu J; Li W; Zhao H
J Cell Biochem; 2020 Apr; 121(4):2970-2980. PubMed ID: 31709629
[TBL] [Abstract][Full Text] [Related]
38. ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.
Liu X; He Y; Wang P; Hu J; Hao C; Wang Q; Yang Y; Sun Y; Ma B; Sun H; Xue D; Meng X
Dis Markers; 2022; 2022():5791471. PubMed ID: 35280441
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
40. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
